Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in moderate to severe pyoderma gangrenosum
NCT06092216Phase 2Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Sep 2023
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of spesolimab in pyoderma gangrenosum (PG), sponsored by Icahn School of Medicine at Mount Sinai. Started Sep 2023; status: terminated.
02
Drugs
spesolimab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT06092216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092216.